Nymox Pharmaceutical
NYMX
#10186
Rank
โ‚น1.64 B
Marketcap
Country
โ‚น18.07
Share price
0.00%
Change (1 day)
N/A
Change (1 year)

Revenue for Nymox Pharmaceutical (NYMX)

Revenue in 2023 (TTM): N/A

In 2022 the company made a revenue of N/A a decrease over the revenue in the year 2021 that were of N/A. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Nymox Pharmaceutical from 1997 to 2023

Annual revenue

Year Revenue Change
2023 (TTM) N/A
2022 N/A
2021 N/A-100%
2020 โ‚น0.36 M-95.54%
2019 โ‚น8.2 M-60.77%
2018 โ‚น20.9 M46.18%
2017 โ‚น14.3 M-25.79%
2016 โ‚น19.27 M-89.5%
2015 โ‚น0.18 B-1.84%
2014 โ‚น0.18 B-9.92%
2013 โ‚น0.20 B23.35%
2012 โ‚น0.16 B2.13%
2011 โ‚น0.16 B430.72%
2010 โ‚น31.03 M60.8%
2009 โ‚น19.3 M-6.25%
2008 โ‚น20.58 M21.01%
2007 โ‚น17.01 M-12.75%
2006 โ‚น19.49 M1.55%
2005 โ‚น19.2 M37.62%
2004 โ‚น13.95 M52.84%
2003 โ‚น9.12 M-46.79%
2002 โ‚น17.15 M51.24%
2001 โ‚น11.34 M7.67%
2000 โ‚น10.53 M-31.3%
1999 โ‚น15.33 M19.99%
1998 โ‚น12.78 M8.32%
1997 โ‚น11.79 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Abbott Laboratories
ABT
โ‚น3.960 TN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น5.671 TN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Quest Diagnostics
DGX
โ‚น980.04 BN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
โ‚น5.367 TN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
โ‚น8.323 TN/A๐Ÿ‡บ๐Ÿ‡ธ USA